Abstract Details
Activity Number:
|
621
|
Type:
|
Invited
|
Date/Time:
|
Thursday, August 7, 2014 : 10:30 AM to 12:20 PM
|
Sponsor:
|
SPAIG Committee
|
Abstract #313178
|
|
Title:
|
Statistical Collaboration Benefits Regulatory Policy
|
Author(s):
|
Lisa LaVange*+
|
Companies:
|
FDA
|
Keywords:
|
external collaborations ;
statistics working groups
|
Abstract:
|
The Office of Biostatistics provides statistical leadership and expertise in the regulation and development of drugs and therapeutic biologics by the US FDA. Our strategic plan calls for clarity of statistical policies and consistency and transparency in their application across regulatory submissions. Collaborations among statisticians and other scientists in government, industry, and academia can greatly enhance our ability to successfully carry out our public health mission. I will discuss three types of both ongoing and potential collaborations with which the office is involved, (i) collaboration with academic statisticians on development of novel statistical methodologies through MOUs and related mechanisms, (ii) participation with our colleagues from industry and academia in working groups sponsored by professional societies and formed to investigate a particular statistical topic of mutual interest, and (iii) collaboration with industry statisticians on clinical informatics initiatives to facilitate sharing of computational tools and software. Results of these various collaborations include, but are not limited to, preparation of white papers and/or peer-reviewed publica
|
Authors who are presenting talks have a * after their name.
Back to the full JSM 2014 program
|
2014 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Professional Development program, please contact the Education Department.
The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
Copyright © American Statistical Association.